Literature DB >> 24857067

Ampullary cancer: an overview.

Daniel H Ahn1, Tanios Bekaii-Saab1.   

Abstract

Ampullary cancers are rare, accounting for only 0.2% of gastrointestinal cancers and approximately 7% of all periampullary cancers. They arise from the ampullary complex, distal to the confluence of the common bile and pancreatic duct (Fig. 1). In contrast to other periampullary malignancies, true ampullary cancers present earlier in their disease course with symptoms that result from biliary obstruction. It is often difficult to distinguish primary ampullary cancers from other periampullary cancers preoperatively. In early stages, ampullary cancers are surgically treated, similar to pancreatic cancers, and typically with a pancreatico-duodenoectomy (or Whipple procedure). Because of their earlier presentation, resection rates for all patients are much higher than other periampullary carcinomas. Moreover, their prognosis tends to be better than those with other periampullary- and pancreatic-originating cancers. In patients with true ampullary cancer, there is very limited data to guide physicians on the choice of therapy, largely because of the rarity of the disease and the paucity of related research. Herein, we provide an overview of the biology, histology, current therapeutic strategies, and potential future therapies for carcinomas arising from the ampulla of Vater.

Entities:  

Mesh:

Year:  2014        PMID: 24857067      PMCID: PMC4966534          DOI: 10.14694/EdBook_AM.2014.34.112

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  24 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.

Authors:  Nicolai A Schultz; Jens Werner; Hanni Willenbrock; Anne Roslind; Nathalia Giese; Thomas Horn; Morten Wøjdemann; Julia S Johansen
Journal:  Mod Pathol       Date:  2012-08-10       Impact factor: 7.842

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.

Authors:  Stefano Cereda; Paolo Passoni; Michele Reni; Maria G Viganò; Luca Aldrighetti; Roberto Nicoletti; Eugenio Villa
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

5.  Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study.

Authors:  S N Agoff; D A Crispin; M P Bronner; D H Dail; S E Hawes; R C Haggitt
Journal:  Mod Pathol       Date:  2001-03       Impact factor: 7.842

6.  Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.

Authors:  Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo
Journal:  Surgery       Date:  2006-08-28       Impact factor: 3.982

7.  Adjuvant chemo-radiotherapy in ampullary cancers.

Authors:  S S Sikora; P Balachandran; K Dimri; N Rastogi; A Kumar; R Saxena; V K Kapoor
Journal:  Eur J Surg Oncol       Date:  2005-03       Impact factor: 4.424

8.  Survival after resection of ampullary carcinoma: a national population-based study.

Authors:  Jessica B O'Connell; Melinda A Maggard; Jesse Manunga; James S Tomlinson; Howard A Reber; Clifford Y Ko; O Joe Hines
Journal:  Ann Surg Oncol       Date:  2008-03-28       Impact factor: 5.344

9.  The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.

Authors:  Seung Tae Kim; Jeeyun Lee; Kyu Taek Lee; Jong Kyun Lee; Kwang Hyuk Lee; Seong-Ho Choi; Jin-Seok Heo; Dong Wook Choi; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Young Suk Park; Won Ki Kang
Journal:  Med Oncol       Date:  2009-11-07       Impact factor: 3.064

10.  Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Authors:  Michael J Overman; Gauri R Varadhachary; Scott Kopetz; Rosni Adinin; E Lin; Jeffrey S Morris; Cathy Eng; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

View more
  20 in total

1.  Initial Experience of ERCP-Guided Radiofrequency Ablation as the Primary Therapy for Inoperable Ampullary Carcinomas.

Authors:  Bing Hu; Bo Sun; Dao-Jian Gao; Jun Wu; Xin Ye; Ming-Xing Xia; Tian-Tian Wang
Journal:  Dig Dis Sci       Date:  2019-09-27       Impact factor: 3.199

2.  Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases.

Authors:  Serdar Balci; Olca Basturk; Burcu Saka; Pelin Bagci; Lauren M Postlewait; Takuma Tajiri; Kee-Taek Jang; Nobuyuki Ohike; Grace E Kim; Alyssa Krasinskas; Hyejeong Choi; Juan M Sarmiento; David A Kooby; Bassel F El-Rayes; Jessica H Knight; Michael Goodman; Gizem Akkas; Michelle D Reid; Shishir K Maithel; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2015-03-18       Impact factor: 5.344

3.  Treatment of cancer patients in their last month of life: aimless chemotherapy.

Authors:  Tarek Assi; Elie El Rassy; Samer Tabchi; Toni Ibrahim; Tania Moussa; Ralph Chebib; Fadi El Karak; Fadi Farhat; Georges Chahine; Fadi Nasr; Marwan Ghosn; Joseph Kattan
Journal:  Support Care Cancer       Date:  2015-09-21       Impact factor: 3.603

4.  The ABO Blood Group Impacts the Survival of Patients Undergoing Pancreatoduodenectomy for Biliary Tract Cancer.

Authors:  Shozo Mori; Taku Aoki; Kazuma Tago; Takayuki Shimizu; Nobuhiro Harada; Kyung-Hwa Park; Yuhki Sakuraoka; Takayuki Shiraki; Yukihiro Iso; Keiichi Kubota
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

5.  Ampullary and pancreatic adenocarcinoma-a comparative study.

Authors:  Marwa Ferchichi; Raja Jouini; Wafa Koubaa; Fatma Khanchel; Imen Helal; Dhafer Hadad; Norsaf Bibani; Aschraf Chadli-Debbiche; Ehsen BenBrahim
Journal:  J Gastrointest Oncol       Date:  2019-04

6.  MicroRNA co-expression networks exhibit increased complexity in pancreatic ductal compared to Vater's papilla adenocarcinoma.

Authors:  Tommaso Mazza; Massimiliano Copetti; Daniele Capocefalo; Caterina Fusilli; Tommaso Biagini; Massimo Carella; Antonio De Bonis; Nicola Mastrodonato; Ada Piepoli; Valerio Pazienza; Evaristo Maiello; Fabio Francesco di Mola; Pierluigi di Sebastiano; Angelo Andriulli; Francesca Tavano
Journal:  Oncotarget       Date:  2017-10-31

7.  KRAS, NRAS and BRAF analysis of ampullary adenocarcinoma classified using CK7, CK20, MUC1 and MUC2.

Authors:  Marwa Ferchichi; Raja Jouini; Imen Ayari; Wafa Koubaa; Aschraf Chadli-Debbiche; Ehsen BenBrahim
Journal:  J Gastrointest Oncol       Date:  2018-10

Review 8.  Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers.

Authors:  Pablo Letelier; Ismael Riquelme; Alfonso H Hernández; Neftalí Guzmán; Jorge G Farías; Juan Carlos Roa
Journal:  Int J Mol Sci       Date:  2016-05-23       Impact factor: 5.923

9.  Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.

Authors:  Gorana Dasic; Thomas Jones; Vera Frajzyngier; Ricardo Rojo; Ann Madsen; Hernan Valdez
Journal:  Pharmacol Res Perspect       Date:  2018-02

10.  Comparison of Laparoscopic and Open Pancreaticoduodenectomy for the Treatment of Nonpancreatic Periampullary Adenocarcinomas.

Authors:  Ling-Wei Meng; Yun-Qiang Cai; Yong-Bin Li; He Cai; Bing Peng
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2018-02       Impact factor: 1.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.